EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome

Nithya Krishnamurthy iD, Daisuke Nishizaki, Scott M Lippman, Hirotaka Miyashita, Mary K Nesline, Sarabjot Pabla, Jeffrey M Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359231220510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 06.01.2024. Verfasst von Nithya Krishnamurthy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574, USA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, RK is funded.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CTLA-4 impedes the immune system’s antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents – ipilimumab and tremelimumab – both used together with anti-PD-1/PD-L1 agents.

Objective

To assess the prognostic implications and immunologic correlates of high CTLA-4 in tumors of patients on immunotherapy and those on non-immunotherapy treatments. Design/methods: We evaluated RNA expression levels in a clinical-grade laboratory and clinical correlates of CTLA-4 and other immune checkpoints in 514 tumors, including 489 patients with advanced/metastatic cancers and full outcome annotation. A reference population (735 tumors; 35 histologies) was used to normalize and rank transcript abundance (0–100 percentile) to internal housekeeping gene profiles.

Results

The most common tumor types were colorectal (140/514, 27%), pancreatic (55/514, 11%), breast (49/514, 10%), and ovarian cancers (43/514, 8%). Overall, 87 of 514 tumors (16.9%) had high CTLA-4 transcript expression (⩾75th percentile rank). Cancers with the largest proportion of high CTLA-4 transcripts were cervical cancer (80% of patients), small intestine cancer (33.3%), and melanoma (33.3%). High CTLA-4 RNA independently/significantly correlated with high PD-1, PD- L2, and LAG3 RNA levels (and with high PD-L1 in univariate analysis). High CTLA-4 RNA expression was not correlated with survival from the time of metastatic disease [ N = 272 patients who never received immune checkpoint inhibitors (ICIs)]. However, in 217 patients treated with ICIs (mostly anti-PD-1/anti-PD- L1), progression-free survival (PFS) and overall survival (OS) were significantly longer among patients with high versus non-high CTLA-4 expression [hazard ratio, 95% confidence interval: 0.6 (0.4–0.9) p = 0.008; and 0.5 (0.3–0.8) p = 0.002, respectively]; results were unchanged when 18 patients who received anti-CTLA-4 were omitted. Patients whose tumors had high CTLA-4 and high PD-L1 did best; those with high PD-L1 but non-high CTLA-4 and/or other expression patterns had poorer outcomes for PFS ( p = 0.004) and OS ( p = 0.009) after immunotherapy.

Conclusion

High CTLA-4, especially when combined with high PD-L1 transcript expression, was a significant positive predictive biomarker for better outcomes (PFS and OS) in patients on immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

biomarker identificationbiomarker validationgenomic signaturesimmunotherapy biomarkersprognostic biomarkersresponse biomarkers

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574, USA.
  • Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA.
  • Dartmouth Cancer Center, Hematology and Medical Oncology, Lebanon, NH, USA.
  • OmniSeq Inc. (Labcorp), Buffalo, NY, USA.
  • MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • WIN Consortium, Paris, France.

ORCID-Profile: Nithya Krishnamurthy

Förderung

  • NCI NIH HHS
  • RK is funded

Zitieren

APA

Krishnamurthy, N., Nishizaki, D., Lippman, S. M., Miyashita, H., Nesline, M. K., Pabla, S., Conroy, J. M., DePietro, P., Kato, S., & Kurzrock, R. (2024). High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359231220510

Vancouver

Krishnamurthy N, Nishizaki D, Lippman SM, Miyashita H, Nesline MK, Pabla S, et al. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231220510

BibTeX
@article{Krishnamurthy2024,
  author = {Krishnamurthy, Nithya and Nishizaki, Daisuke and Lippman, Scott M and Miyashita, Hirotaka and Nesline, Mary K and Pabla, Sarabjot and Conroy, Jeffrey M and DePietro, Paul and Kato, Shumei and Kurzrock, Razelle},
  title = {High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359231220510}
}
Kostenlos starten →